Taken together, these observations suggest that all the ERBB3 variants can be targeted in ERBB3/ERBB2 heterodimeric complexes with anti-ERBB antibodies or TKI’s but that the sensitivity may depend on the availability of activating ligands in the tumor microenvironment. The gene discussed is EGFR; the disease is neoplasm.